Nutritional management of hyperapoB - PubMed

Affiliations

• PMID: 27821191
• DOI: 10.1017/S0954422416000147

Review

Nutritional management of hyperapoB

Valérie Lamantia et al. Nutr Res Rev. 2016 Dec.

Abstract

Plasma apoB is a more accurate marker of the risk of CVD and type 2 diabetes (T2D) than LDL-cholesterol; however, nutritional reviews targeting apoB are scarce. Here we reviewed eighty-seven nutritional studies and present conclusions in order of strength of evidence. Plasma apoB was reduced in all studies that induced weight loss of 6-12 % using hypoenergetic diets (seven studies; 5440-7110 kJ/d; 1300-1700 kcal/d; 34-50 % carbohydrates; 27-39 % fat; 18-24 % protein). When macronutrients were compared in isoenergetic diets (eleven studies including eight randomised controlled trials (RCT); n 1189), the diets that reduced plasma apoB were composed of 26-51 % carbohydrates, 26-46 % fat, 11-32 % protein, 10-27 % MUFA, 5-14 % PUFA and 7-13 % SFA. Replacement of carbohydrate by MUFA, not SFA, decreased plasma apoB. Moreover, dietary enriching with n-3 fatty acids (FA) (from fish: 1·1-1·7 g/d or supplementation: 3·2-3·4 g/d EPA/DHA or 4 g/d EPA), psyllium (about 8-20 g/d), phytosterols (about 2-4 g/d) or nuts (30-75 g/d) also decreased plasma apoB, mostly in hyperlipidaemic subjects. While high intake of trans-FA (4·3-9·1 %) increased plasma apoB, it is unlikely that these amounts represent usual consumption. Inconsistent data existed on the effect of soya proteins (25-30 g/d), while the positive association of alcohol consumption with low plasma apoB was reported in cross-sectional studies only. Five isoenergetic studies using Mediterranean diets (including two RCT; 823 subjects) reported a decrease of plasma apoB, while weaker evidence existed for Dietary Approaches to Stop Hypertension (DASH), vegetarian, Nordic and Palaeolithic diets. We recommend using a Mediterranean dietary pattern, which also encompasses the dietary components reported to reduce plasma apoB, to target hyperapoB and reduce the risks of CVD and T2D.

Keywords: CHO carbohydrate; DASH Dietary Approaches to Stop Hypertension; FA fatty acid; HDL-C HDL-cholesterol; LDL-C LDL-cholesterol; Lp(a) lipoprotein (a); MCFA medium-chain fatty acid; Med diet Mediterranean diet; RCT randomised controlled trial; RESMENA Reduction of the Metabolic Syndrome in Navarra-Spain; T2D type 2 diabetes; TRL TAG-rich lipoprotein; VLDL-C VLDL-cholesterol; hyperapoB hyperapobetalipoproteinaemia; non-HDL-C non-HDL-cholesterol; ApoB-lipoproteins; Behaviour modification programmes; Cardiometabolic risks; LDL.

Similar articles

• Replacing dietary palmitic acid with elaidic acid (t-C18:1 delta9) depresses HDL and increases CETP activity in cebus monkeys.

  Khosla P, Hajri T, Pronczuk A, Hayes KC. Khosla P, et al. J Nutr. 1997 Mar;127(3):531S-536S. doi: 10.1093/jn/127.3.531S. J Nutr. 1997. PMID: 9082041

• High carbohydrate and high monounsaturated fatty acid diets similarly affect LDL electrophoretic characteristics in men who are losing weight.

  Archer WR, Lamarche B, St-Pierre AC, Mauger JF, Dériaz O, Landry N, Corneau L, Després JP, Bergeron J, Couture P, Bergeron N. Archer WR, et al. J Nutr. 2003 Oct;133(10):3124-9. doi: 10.1093/jn/133.10.3124. J Nutr. 2003. PMID: 14519795 Clinical Trial.

• The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials.

  Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, Jenkins AL, Vuksan V. Ho HV, et al. Br J Nutr. 2016 Oct;116(8):1369-1382. doi: 10.1017/S000711451600341X. Epub 2016 Oct 11. Br J Nutr. 2016. PMID: 27724985 Review.

• Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update.

  Ooi EM, Watts GF, Ng TW, Barrett PH. Ooi EM, et al. Nutrients. 2015 Jun 2;7(6):4416-25. doi: 10.3390/nu7064416. Nutrients. 2015. PMID: 26043038 Free PMC article. Review.

Cited by

• LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue.

  Faraj M. Faraj M. J Biomed Res. 2020 Mar 12;34(4):251-259. doi: 10.7555/JBR.34.20190124. J Biomed Res. 2020. PMID: 32701068 Free PMC article.

• Association of Empirical Dietary Atherogenic Indices with All-Cause and Cause-Specific Mortality in a Multi-Ethnic Adult Population of the United States.

  Mazidi M, Katsiki N, Mikhailidis DP, Bartłomiejczyk MA, Banach M. Mazidi M, et al. Nutrients. 2019 Oct 1;11(10):2323. doi: 10.3390/nu11102323. Nutrients. 2019. PMID: 31581458 Free PMC article.

• Mediterranean diet and time-restricted eating as a cardiac rehabilitation approach for patients with coronary heart disease and pre-diabetes: the DIABEPIC-1 protocol of a feasibility trial.

  Iglesies-Grau J, Dionne V, Latour É, Gayda M, Besnier F, Gagnon D, Debray A, Gagnon C, Pelletier V, Nigam A, L'Allier PL, Juneau M, Bouabdallaoui N, Bherer L. Iglesies-Grau J, et al. BMJ Open. 2023 Oct 17;13(10):e073763. doi: 10.1136/bmjopen-2023-073763. BMJ Open. 2023. PMID: 37848307 Free PMC article.

• Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors.

  Dansinger ML, Williams PT, Superko HR, Schaefer EJ. Dansinger ML, et al. Lipids Health Dis. 2019 Jul 17;18(1):154. doi: 10.1186/s12944-019-1094-4. Lipids Health Dis. 2019. PMID: 31311555 Free PMC article.

• Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target.

  Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, De Leon J, Glass AD, Reiss AB. Behbodikhah J, et al. Metabolites. 2021 Oct 8;11(10):690. doi: 10.3390/metabo11100690. Metabolites. 2021. PMID: 34677405 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Cambridge University Press

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal